---
title: "A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS"
description: "This study is being done to evaluate the safety and effectiveness of APTO-253 for the treatment of patients with the condition of acute myelogenous leukemi"
url: "https://www.clareohealth.com/clinical-trials/NCT02267863"
---

This study is being done to evaluate the safety and effectiveness of APTO-253 for the treatment of patients with the condition of acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) for which either the standard treatment has failed, is no longer effective, or can no longer be administered safely or poses a risk for your general well being.

## Key Facts

**ID:** NCT02267863
**Status:** TERMINATED
**Phase:** PHASE1
**Type:** INTERVENTIONAL
**Enrollment:** 21
**Sponsor:** Aptose Biosciences Inc.

## About This Study

This clinical trial is testing APTO-253, a new treatment, in patients with relapsed or refractory acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to evaluate the safety and effectiveness of this drug in patients whose previous treatments have not worked or are no longer safe.

## Detailed Description

This is a multicenter, open-label, Phase Ia/b dose escalation study of safety, pharmacodynamics, and pharmacokinetics of APTO-253 in ascending cohorts (3+3 design) to determine the MTD or recommended dose in patients with relapsed or refractory acute myelogenous leukemia (AML) or high-risk MDS patients. This is to be followed by a cohort expansion phase at the MTD or recommended dose.

## Conditions

- Acute Myelogenous Leukemia in Relapse
- Acute Myelogenous Leukemia, Relapsed, Adult
- Acute Myelogenous Leukemia, Adult
- Acute Myelogenous Leukemia
- High Risk Myelodysplasia

## Interventions

**DRUG: APTO-253**
APTO-253 will be given in ascending doses starting at 20 mg/m2 until the maximum tolerated dose or recommended dose is reached.

## Eligibility

Inclusion Criteria: * Patients ≥18 years old * Life expectancy of at least 2 months * Off previous cancer therapy for at least 14 days, or 5 half-lives for noncytotoxic agents pri…

## Who Can Participate

**Minimum age:** 18

**Sex:** ALL

**Accepts healthy volunteers:** No

## Study Locations

- University of Arizona Cancer Center, Tucson, Arizona, United States
- UC San Diego Moores Cancer Center, La Jolla, California, United States
- University of California, Irvine, Orange, California, United States
- Emory University; Winship Cancer Institute, Atlanta, Georgia, United States
- Ochsner Cancer Institute, New Orleans, Louisiana, United States
- University of Michigan, Ann Arbor, Michigan, United States
- St. Vincent Frontier Cancer Center, Billings, Montana, United States
- University of Rochester; Wilmot Cancer Institute Clinical Trials Office, Rochester, New York, United States
- University Hospital, Cleveland, Ohio, United States
- Oregon Health & Science University, Portland, Oregon, United States
- Prisma Health, Institute for Translational Oncology Research, Greenville, South Carolina, United States
- Baylor Research Institute, Dallas, Texas, United States
- MD Anderson Cancer Center, Houston, Texas, United States

## Contact Information

## Important Dates

**Study start:** October 1, 2014

**Completion date:** September 1, 2021

**Last updated:** August 22, 2022

## Consider Discussing with Your Care Team

### Worth Discussing If

- You have relapsed or refractory acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (MDS).
- Your previous treatments have not been successful or are no longer safe.
- You are looking for new treatment options and are willing to participate in a clinical trial.

### Questions to Ask

- What are the potential side effects of APTO-253?
- How does this treatment compare to my current options?
- What will the treatment schedule look like?
- How will my health be monitored during the trial?
- What happens if I experience side effects?
- Are there any travel requirements for participating in this trial?

[View on ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02267863)
